| 1421 |
National Cancer Institute |
Html |
en |
Gastrointestinal Complications (PDQ®)–Patient Version |
Expert-reviewed information summary about constipation, impaction, bowel obstruction, and diarrhea as complications of cancer or its treatment. The management of these problems is discussed. |
| red blood cells | 0.59878 |
| stool | 0.665289 |
| cancer treatment | 0.386923 |
| acute enteritis | 0.365068 |
| general signs | 0.397049 |
| Fecal occult blood | 0.425816 |
| bowel movements | 0.59883 |
| body | 0.382296 |
| PDQ cancer information | 0.480572 |
| low blood pressure | 0.378182 |
| Acute bowel obstructions | 0.360846 |
| white blood cells | 0.495045 |
| normal bowel function | 0.348728 |
| Digital rectal exam | 0.477206 |
| radiation enteritis | 0.451513 |
| clinical trials | 0.412365 |
| bowel movement | 0.9808 |
| cancer information summary | 0.416977 |
| constipation | 0.510652 |
| clinical trial | 0.351928 |
| blood pressure | 0.387153 |
| patients | 0.595376 |
| cancer patients | 0.514161 |
| diarrhea | 0.490455 |
| dry stool | 0.353386 |
|
| symptoms | 0.370324 |
| watery bowel movements | 0.352417 |
| NCI PDQ cancer | 0.351977 |
| radiation therapy | 0.58958 |
| occult blood test | 0.398605 |
| rectum | 0.509438 |
| small intestine | 0.391741 |
| fecal impaction | 0.927514 |
| stool softeners | 0.403803 |
| treatment | 0.634263 |
| medicines | 0.37024 |
| bowel obstructions | 0.392819 |
| abdomen | 0.481971 |
| bowel obstruction | 0.468528 |
| National Cancer Institute | 0.437526 |
| Cancer Care | 0.355451 |
| energy beam | 0.402215 |
| acute radiation enteritis | 0.392407 |
| GI complications | 0.360144 |
| PDQ summary | 0.394667 |
| doctor | 0.384993 |
| bowel sounds | 0.369971 |
| cancer | 0.734003 |
| large intestine | 0.487328 |
|
CLICK HERE |
| 1464 |
National Cancer Institute |
Html |
en |
Malignant Mesothelioma Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of malignant mesothelioma. |
| standard treatment option | 0.662037 |
| relatively long survival | 0.763744 |
| definitive surgery | 0.66758 |
| advanced mesothelioma | 0.746687 |
| major symptomatic problems | 0.680779 |
| chemotherapy | 0.784047 |
| worst prognostic group | 0.744191 |
| sarcomatoid mesothelioma | 0.794135 |
| bland tumor cells | 0.677183 |
| recurrence-free survival | 0.667934 |
| clinical trials | 0.794592 |
| important prognostic factor. | 0.728634 |
| Median survival | 0.786141 |
| randomized study | 0.677593 |
| patients | 0.897231 |
| survival | 0.852167 |
| useful immunohistochemical stains | 0.67583 |
| CALGB prognostic group | 0.748668 |
| progression-free survival rate | 0.733148 |
| Cooperative Oncology Group | 0.690912 |
| neoadjuvant chemotherapy | 0.666321 |
| survival times | 0.760237 |
| prognostic value | 0.740005 |
| radiation therapy | 0.723289 |
|
| improved survival | 0.661891 |
| poorer survival | 0.696893 |
| aggressive treatment approaches | 0.668925 |
| different treatment modalities | 0.670393 |
| aggressive surgical approaches | 0.806279 |
| CALGB index | 0.684276 |
| mesothelioma diagnoses. | 0.716989 |
| Desmoplastic mesothelioma | 0.719754 |
| epithelioid mesothelioma | 0.727094 |
| adjuvant radiation therapy | 0.676072 |
| mesothelioma | 0.925011 |
| Advanced Malignant Mesothelioma | 0.78476 |
| tissue specimens | 0.675675 |
| malignant pleural mesothelioma | 0.822532 |
| first-line chemotherapy | 0.674756 |
| white blood cell | 0.694326 |
| first-line combination chemotherapy | 0.748058 |
| recurrent malignant mesothelioma | 0.883067 |
| extrapleural pneumonectomy | 0.673182 |
| malignant pleural disease | 0.743809 |
| large randomized study | 0.671727 |
| PDQ summary | 0.685413 |
| improved long-term survival | 0.756886 |
| prognostic groups | 0.660571 |
|
CLICK HERE |
| 1534 |
National Cancer Institute |
Html |
en |
Cartilage (Bovine and Shark) (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the use of bovine and shark cartilage as a treatment for people with cancer. Note: The information in this summary is no longer being updated and is provided for reference purposes only. |
| angiogenesis inhibitor | 0.605921 |
| cartilage factor | 0.525431 |
| cartilage research | 0.52625 |
| cartilage powder | 0.542054 |
| cartilage treatment | 0.554222 |
| shark cartilage | 0.973124 |
| shark cartilage extracts | 0.55218 |
| Biol Response Mod | 0.51035 |
| cartilage cells | 0.557954 |
| new blood vessels | 0.487052 |
| tumor angiogenesis | 0.46716 |
| dry shark cartilage | 0.564932 |
| bovine cartilage | 0.627952 |
| patients | 0.494925 |
| Natl Cancer Inst | 0.505572 |
| vascular endothelial growth | 0.488146 |
| novel shark cartilage | 0.566963 |
| bovine cartilage extract | 0.544409 |
| bovine cartilage extracts | 0.534781 |
| shark cartilage extract | 0.575893 |
| powdered shark cartilage | 0.660454 |
| metastatic renal cell | 0.492793 |
| Japanese shark cartilage | 0.557325 |
| new endothelial cells | 0.468808 |
|
| shark cartilage products | 0.552328 |
| endothelial cells | 0.499823 |
| cartilage products | 0.616806 |
| Oral shark cartilage | 0.568829 |
| angiogenesis inhibitors | 0.486536 |
| PUBMED Abstract | 0.506075 |
| epiphyseal cartilage | 0.523025 |
| cartilage tissue | 0.520334 |
| endothelial cell proliferation | 0.510942 |
| bovine cartilage preparations | 0.556431 |
| human cartilage | 0.516475 |
| shark cartilage-derived angiogenesis | 0.484691 |
| Catrix treatment | 0.468204 |
| shark cartilage product | 0.595815 |
| cartilage therapy | 0.532177 |
| Abstract | 0.525209 |
| endothelial cell | 0.516176 |
| renal cell carcinoma | 0.554811 |
| phase i/ii trial | 0.471371 |
| cartilage-derived collagenase inhibitor | 0.469151 |
| tumor | 0.475092 |
| shark cartilage inhibitor | 0.566866 |
| cancer | 0.518101 |
| bovine cartilage therapies | 0.544621 |
|
CLICK HERE |
| 1727 |
National Cancer Institute |
Html |
en |
Bone Cancer |
A fact sheet about the diagnosis and treatment of cancers that develop in the bones. |
| benign bone tumors | 0.382978 |
| soft tissue | 0.317275 |
| osteoid tissue | 0.26524 |
| uncommon cancer | 0.255981 |
| primary bone cancer | 0.577561 |
| cancer cells | 0.329155 |
| abnormal bone tissue | 0.376855 |
| metastatic cancer | 0.262213 |
| bone scan | 0.325169 |
| anticancer drugs | 0.274172 |
| Cancer Information Service | 0.273277 |
| Yes. Cancer | 0.261575 |
| tumor causes production | 0.259064 |
| healthy bone tissue | 0.408981 |
| Yes. Bone cancer | 0.36265 |
| Cancer Treatment Research | 0.2781 |
| preoperative tumor treatment | 0.265675 |
| healthy tissue | 0.254742 |
| fibrous tissue | 0.263622 |
| clinical trials | 0.344137 |
| bone tissue | 0.452141 |
| primitive nerve tissue | 0.285777 |
| heredity cancer syndromes | 0.279206 |
| normal bone tissue | 0.410848 |
|
| Clinical Trials page | 0.251984 |
| Ewing Sarcoma Family | 0.249697 |
| soft tissue sarcomas | 0.285733 |
| incisional biopsy | 0.250026 |
| tissue sample | 0.258655 |
| blood vessels | 0.251489 |
| high-dose external radiation | 0.249703 |
| spongy tissue | 0.268691 |
| bone marrow | 0.344367 |
| cancer centers | 0.251332 |
| different types | 0.282598 |
| doctor | 0.249686 |
| new bone cells | 0.361397 |
| bones | 0.259461 |
| important treatment option | 0.251744 |
| radiation therapy | 0.277888 |
| treatment options | 0.263715 |
| bone cancer | 0.911469 |
| comprehensive cancer information | 0.27281 |
| research studies | 0.263781 |
| cancerous bone cells | 0.36956 |
| bone cancers | 0.35903 |
| African American children | 0.253491 |
|
CLICK HERE |
| 1889 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de colon (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de colon. |
| siguientes procedimientos | 0.92972 |
| pequeña cantidad | 0.497446 |
| estadio ii | 0.856655 |
| tubo recolector | 0.46569 |
| rayos x | 0.562684 |
| inferior.ampliar procedimiento | 0.480242 |
| enlace drugs approved | 0.587222 |
| escáner tep | 0.457465 |
| proteÃna llamada factor | 0.458005 |
| National Cancer Institute | 0.432943 |
| sustancia llamada gadolinio | 0.497309 |
| siguientes riesgos | 0.425516 |
| Instituto Nacional | 0.460477 |
| PDQ Tratamiento | 0.671072 |
| estadio iiia | 0.656788 |
| antecedentes familiares | 0.459139 |
|
| estadio iiic | 0.63832 |
| cáncer.ampliar sigmoidoscopia | 0.46788 |
| estadio iiib | 0.647408 |
| estadio iia | 0.819513 |
| estadio iic | 0.81663 |
| células cancerosas.El bevacizumab | 0.49983 |
| Physician Data Query | 0.524312 |
| Rectal Cancer | 0.499997 |
| cuerpo).ampliar anatomÃa | 0.468805 |
| crecer.El ziv-aflibercept | 0.437476 |
| antÃgeno carcinoembrionario | 0.577035 |
| PDQ Cánceres | 0.540215 |
| colon forma | 0.990115 |
| tejidos sanos circundantes | 0.470011 |
| Estadio IVA | 0.522216 |
| siguientes pruebas | 0.469066 |
|
CLICK HERE |
| 1995 |
National Cancer Institute |
Html |
es |
Tratamiento de la histiocitosis de células de Langerhans (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el tratamiento de la histiocitosis de células de Langerhans infantil. |
| Immunol Cell Biol | 0.40642 |
| langerhans cell | 0.852012 |
| lesiones hcl | 0.406571 |
| with langerhans | 0.417161 |
| langerhans cell histiocytosis | 0.986891 |
| multisystem langerhans | 0.422209 |
| BRAF V600E-negative Langerhans | 0.406114 |
| Langerhans-cell histiocytosis | 0.403191 |
| cutaneous langerhans | 0.405301 |
| células dendrÃticas mieloides | 0.413633 |
| BRAF Mutation Correlates | 0.403764 |
| braf mutation | 0.404571 |
| pulmonary langerhans | 0.409447 |
| pediatric-onset multisystem langerhans | 0.405705 |
| HCL multisistémica | 0.436981 |
| pulmonary langerhans cell | 0.407403 |
| Grois N | 0.403041 |
| cell histiocytosis patients | 0.407759 |
| Cell Histiocytosis Study | 0.404713 |
| cell histiocytosis harboring | 0.404154 |
| mutación v600e | 0.406931 |
| dendritic cell differentiation | 0.403188 |
| mutación braf v600e | 0.411753 |
| histiocytosis lesions reveals | 0.403971 |
| Arch Dis Child | 0.403576 |
|
| Emile JF | 0.403241 |
| epidermal langerhans cells | 0.412171 |
| HCL dérmica | 0.409229 |
| BRAF V600E | 0.436151 |
| Pediatr Blood Cancer | 0.419983 |
| lesiones óseas | 0.406722 |
| With High-Risk Langerhans | 0.411149 |
| mutaciones braf v600e | 0.404471 |
| Multiresistant Langerhans Cell | 0.407509 |
| mutación braf | 0.412372 |
| braf inhibitor | 0.402661 |
| Med Pediatr Oncol | 0.402927 |
| Clin Oncol | 0.402664 |
| with braf | 0.403023 |
| células circulantes | 0.409275 |
| adult pulmonary langerhans | 0.405666 |
| HCL CD1a-positivas | 0.409797 |
| Langerhans'-cell histiocytosis | 0.405031 |
| High-Risk Langerhans Cell | 0.421727 |
| oncogén braf | 0.403238 |
| tratamiento inicial.la hcl | 0.405836 |
| with epidermal langerhans | 0.411581 |
| childhood langerhans | 0.408867 |
| French Langerhans | 0.405677 |
|
CLICK HERE |
| 2043 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de ovario, de trompas de Falopio y primario de peritoneo (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre los factores que influyen en el riesgo de presentar cáncer de ovario, de trompas de Falopio y primario de peritoneo y sobre las investigaciones dirigidas a la prevención de los mismos. |
| Obstet Gynecol | 0.31235 |
| oral contraceptives | 0.309215 |
| factores alimentarios | 0.305635 |
| histologic subtype | 0.312055 |
| Cancer Cohort Consortium | 0.318833 |
| Colorectal Cancer | 0.308524 |
| cancer risk factors | 0.338538 |
| An Analysis From | 0.306638 |
| Lacey JV Jr | 0.313268 |
| individual participant meta-analysis | 0.306651 |
| American Cancer Society | 0.315301 |
| Prospective Investigation into | 0.306516 |
| Ovarian Cancer Association | 0.322566 |
| Trabert B | 0.318769 |
| National Institutes | 0.306184 |
| Cancer Prev | 0.318672 |
| ovarian cancer | 0.962228 |
| bilateral oophorectomy | 0.306539 |
| population-based study | 0.305827 |
| Natl Cancer Inst | 0.339156 |
| múltiples estudios | 0.32855 |
| California Teachers Study | 0.307709 |
| Health Study Cohort | 0.31028 |
| hormone replacement therapy | 0.312605 |
| Beral V | 0.305906 |
|
| European Prospective Investigation | 0.306439 |
| investigation into cancer | 0.318863 |
| SEER Cancer Statistics | 0.308163 |
| Cancer Association Consortium | 0.318478 |
| cohort study | 0.309167 |
| prospectively studied cohort | 0.307037 |
| Midwifery Womens Health | 0.306899 |
| health study | 0.334114 |
| Cancer Facts | 0.308362 |
| tumores tipo | 0.310257 |
| National Cancer Institute | 0.308306 |
| ovarian cancer risk | 0.650797 |
| epidemiological studies | 0.315154 |
| antecedentes familiares | 0.31063 |
| nih-aarp diet | 0.308944 |
| carcinomas ováricos tipo | 0.305728 |
| Netherlands cohort study | 0.308948 |
| Gynecologic Cancers | 0.321276 |
| Yang HP | 0.306882 |
| Ovarian Cancer Cohort | 0.322781 |
| PDQ Genetics | 0.322297 |
| hormone-related risk factors | 0.30545 |
| Health-AARP Diet | 0.307792 |
| Women’s Health Initiative | 0.307189 |
|
CLICK HERE |
| 15647 |
National Cancer Institute |
Html |
en |
Genomic Data Sharing (GDS) Policy Contact Information |
Genomic Data Sharing Policy contact information, including NCI-Designated GPAs by division or center. |
| GPA assistant | 0.93001 |
| Cancer Training | 0.249467 |
| Shannon Hughes | 0.229368 |
| Sean Hanlon | 0.257761 |
| NIH GDS Policy | 0.610914 |
| Guidry Auvil Daniela | 0.496929 |
| NCI division | 0.258673 |
| Anil Wali Emmanuel | 0.495613 |
| Program Director | 0.234183 |
| Susan Perkins | 0.231974 |
| Cancer Genomics | 0.271538 |
|
| Claire Zhu | 0.249716 |
| Kathleen Calzone Anjan | 0.535993 |
| NCI-specific questions | 0.235899 |
| Cancer Epidemiology | 0.243639 |
| email GDS | 0.354202 |
| Cancer Health Disparities | 0.465506 |
| Natalia Abrams | 0.263564 |
| Cancer Research | 0.254684 |
| Cancer Prevention | 0.23825 |
| genomic program administrator | 0.461255 |
| Strategic Scientific Initiatives | 0.388719 |
|
CLICK HERE |
| 16203 |
National Cancer Institute |
Html |
en |
Ribociclib Improves Progression-Free Survival for Some Women with Metastatic Breast Cancer |
A summary of interim results from a phase III trial testing ribociclib plus letrozole (Femara®) as a first-line treatment for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. |
| Novartis Pharmaceuticals | 0.50861 |
| M.D. | 0.440705 |
| Postmenopausal women | 0.52856 |
| control group | 0.563284 |
| second-line therapy | 0.517854 |
| proteins—cyclin-dependent kinase | 0.519068 |
| CDK4/6 inhibitor | 0.52299 |
| Gabriel N. Hortobagyi | 0.621331 |
| ribociclib arm | 0.512946 |
| median follow-up | 0.54408 |
| significantly more neutropenia | 0.507111 |
| overall survival | 0.538115 |
| Alexandra Zimmer | 0.526907 |
| greater share | 0.502287 |
| infections | 0.43551 |
| Cancer Research | 0.512142 |
| first-line treatment | 0.673992 |
| tumor cells | 0.508198 |
| median progression-free survival | 0.787416 |
| clinical trial | 0.51962 |
| significant benefit | 0.498831 |
| letrozole | 0.459254 |
| ribociclib group | 0.78322 |
| first-line therapy | 0.552793 |
|
| disease | 0.421331 |
| MD Anderson Cancer | 0.627314 |
| progression-free survival | 0.953616 |
| placebo group | 0.714241 |
| careful monitoring | 0.503418 |
| patients | 0.470449 |
| planned interim analysis | 0.594125 |
| adverse events | 0.50283 |
| improvement | 0.435679 |
| Medicine | 0.420889 |
| higher rate | 0.49447 |
| NCI’s Center | 0.505585 |
| University | 0.421021 |
| favor | 0.420251 |
| HER2-negative metastatic breast | 0.65043 |
| certain types | 0.509753 |
| Texas | 0.421011 |
| metastatic breast cancer | 0.821955 |
| colleagues | 0.422295 |
| New England Journal | 0.621204 |
| HER2-negative breast cancer | 0.726717 |
| Femara® | 0.421383 |
| Dr. Zimmer | 0.591472 |
|
CLICK HERE |
| 16859 |
National Cancer Institute |
Html |
en |
Annual Reporting and Auditing |
Reporting helps ensure desired results are achieved throughout the grants lifecycle. Learn more about reporting and auditing requirements for cancer research grants. |
| audit requirements | 0.743431 |
| expenditure data | 0.682542 |
| recipient organization | 0.553305 |
| Interagency Edison | 0.55337 |
| specific grant | 0.551262 |
| budget period | 0.798124 |
| frequent reporting | 0.683485 |
| GPO Stock | 0.544524 |
| foreign organizations | 0.54552 |
| competing project period | 0.68277 |
| federal government | 0.548657 |
| management staff review | 0.661754 |
| federal support | 0.55664 |
| Financial operations | 0.549474 |
| for-profit hospitals | 0.543055 |
| financial expenditure reports | 0.726911 |
| NIH Grants Policy | 0.987592 |
| financial status | 0.557124 |
| NCI Program | 0.553741 |
| cash transaction data | 0.661127 |
| For-profit organizations | 0.556895 |
| individual award requirements | 0.714539 |
| recipient organizations | 0.564783 |
| multiple PIs | 0.556136 |
| award process | 0.560959 |
|
| grants management staff | 0.941167 |
| common reports | 0.590648 |
| recipients | 0.59377 |
| annual basis | 0.550363 |
| annual reports | 0.571527 |
| grant award | 0.582091 |
| different schedule | 0.553636 |
| Contact PI | 0.548816 |
| federal awards | 0.687649 |
| local government audit | 0.75977 |
| progress report | 0.54964 |
| subsequent budget period | 0.690671 |
| eRA Commons | 0.887345 |
| grant activity | 0.54536 |
| annual audit | 0.999887 |
| official accounting records | 0.673267 |
| nonprofit organizations | 0.546576 |
| NIH support | 0.566195 |
| non-competing continuation | 0.568684 |
| Financial reports | 0.562828 |
| generally accepted government | 0.654669 |
| government auditing standards | 0.89142 |
| Grants Policy Statement | 0.964206 |
| financial related audit | 0.753867 |
|
CLICK HERE |